drugset / Trial / NCT06526624
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2027-11-30
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20093 | Other / unclassified | 8 mg/kg | Intravenous |